Open Access

Intra‑tumoral treatment with oxygen‑ozone in glioblastoma: A systematic literature search and results of a case series

  • Authors:
    • Richard Megele
    • Markus J. Riemenschneider
    • Frank Dodoo‑Schittko
    • Matthias Feyrer
    • Andrea Kleindienst
  • View Affiliations

  • Published online on: September 5, 2018     https://doi.org/10.3892/ol.2018.9397
  • Pages: 5813-5822
  • Copyright: © Megele et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Despite progress in surgery and radiochemotherapy, the prognosis of glioblastoma (GB) remains poor. GB cells exhibit a preference for hypoxia to maintain their tumor‑forming capacity. Treatment strategies utilizing oxygen (O2) or ozone (O3) and generating reactive oxygen species induce cell growth inhibition and apoptosis. The anti‑tumorigenic properties of O2‑O3 are accompanied by a key role in regulating immunogenicity. The present study reported a case series of an intra‑tumoral O2‑O3 application in recurrent GB. Following surgery in combination with standard radiochemotherapy, O2‑O3 (5 ml at 40 µg/ml) was applied every four weeks into the tumor vicinity. The patients received a median of 27 (range, 3‑44) O2‑O3 applications. In addition, a systematic literature search was performed in order to evaluate the role of O3 in the treatment of malignancies. The median overall survival rate was 40 (range, 16‑53) months. The median survival rate following the first recurrence or the initiation of the O2‑O3 treatment, respectively, was 34 (range, 12‑53) months. In one patient, a local infection and in another, hemorrhage occurred, necessitating in both the temporary removal of the reservoir. The data from the present study support the potential benefit of an intra‑tumoral O2‑O3 application in recurrent GB. The scientific literature revealed by the bibliographic search suggests that O3 may be considered a viable adjuvant therapy in oncological patients. The present study may serve as a starting point for further observational and clinical studies elucidating the cellular and systemic effects of O2 and/or O3 and demonstrating their efficacy and safety in larger patient samples.
View Figures
View References

Related Articles

Journal Cover

November-2018
Volume 16 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Megele R, Riemenschneider MJ, Dodoo‑Schittko F, Feyrer M and Kleindienst A: Intra‑tumoral treatment with oxygen‑ozone in glioblastoma: A systematic literature search and results of a case series. Oncol Lett 16: 5813-5822, 2018.
APA
Megele, R., Riemenschneider, M.J., Dodoo‑Schittko, F., Feyrer, M., & Kleindienst, A. (2018). Intra‑tumoral treatment with oxygen‑ozone in glioblastoma: A systematic literature search and results of a case series. Oncology Letters, 16, 5813-5822. https://doi.org/10.3892/ol.2018.9397
MLA
Megele, R., Riemenschneider, M. J., Dodoo‑Schittko, F., Feyrer, M., Kleindienst, A."Intra‑tumoral treatment with oxygen‑ozone in glioblastoma: A systematic literature search and results of a case series". Oncology Letters 16.5 (2018): 5813-5822.
Chicago
Megele, R., Riemenschneider, M. J., Dodoo‑Schittko, F., Feyrer, M., Kleindienst, A."Intra‑tumoral treatment with oxygen‑ozone in glioblastoma: A systematic literature search and results of a case series". Oncology Letters 16, no. 5 (2018): 5813-5822. https://doi.org/10.3892/ol.2018.9397